Influenza A H1N1 - Acute Pulmonary Infections
Per the Centers for Disease Control (CDC), the 2016-2017 influenza season has peaked, and flu activity is low in the United States.
2009 H1N1 Pandemic:
In April 2009, the CDC identified in US patients a novel influenza A H1N1 virus characterized by a unique combination of gene segments not previously seen. Also referred to as pandemic H1N1 2009 influenza virus, novel swine-origin influenza A (H1N1) virus (S-OIV), H1N1 flu, and swine flu, it is a quadruple reassortant virus containing genes from 2 swine influenza viruses known to circulate in pigs in North America and Eurasia as well as genes from avian and human influenza viruses. Unlike previously documented cases of swine influenza A/H1N1 infection in humans, the 2009 virus spread easily among humans with no pig exposure. It is now considered a regular human flu virus and continues to circulate seasonally worldwide.
The most common mild symptoms are fever, cough, and sore throat, with a quarter of patients experiencing diarrhea and/or vomiting. However, the clinical spectrum does include severe outcomes including respiratory failure and death. Many patients have fever, cough, dyspnea or respiratory distress, increased serum lactate dehydrogenase levels, bilateral patchy pneumonia, increased creatine kinase level, and lymphopenia. Requirement for mechanical ventilation and death can occur.
Patients at highest risk for severe illness and complications are children aged younger than 5 years, children and adults of any age with underlying chronic medical conditions, and pregnant women. Of note, rates of hospitalization and morbidity have been proportionately lower for people aged older than 60, perhaps because those born before 1957 had previous exposure to influenza A H1N1 strains, which disappeared from circulation for about 20 years after the 1957 influenza A H2N2 pandemic. Even so, adults aged 65 and older are currently defined as being at high risk for complications.
Secondary complications likely include primary viral pneumonia and secondary bacterial pneumonia (specifically, group A streptococci, Staphylococcus aureus, and Streptococcus pneumoniae), including ventilator-associated pneumonia (eg, from Acinetobacter baumannii, Achromobacter xylosoxidans, methicillin-resistant Staphylococcus aureus [MRSA], or Escherichia coli).
H1N1 outbreaks have differed from those of seasonal influenza in the following ways:
- Atypical timing (seasonal influenza is usually observed from October through mid-May in the United States).
- A shift in the age groups most severely affected to a younger population.
- The percentage of deaths is highest (39%) among people aged 25-49 years, followed by people aged 50-64 years (25%). (Seasonal influenza estimated percentage is 90% in people aged older than 65.)
The incubation period for novel influenza A H1N1 infection appears to be 2-7 days, with patients likely contagious 1 day prior through 7 days after the onset of symptoms or until symptoms resolve. An annual vaccine is available for seasonal influenza and includes protection against the influenza A H1N1 virus.
Pediatric Patient Considerations:
The infectious period could be longer in young children. As with seasonal influenza, children aged younger than 5 years are at higher risk for severe complications.
Immunocompromised Patient Considerations:
The infectious period could be longer in immunocompromised or severely ill patients. As with seasonal influenza, immunocompromised patients – including pregnant women – are among those at highest risk for severe complications.
J09.X2 – Influenza due to identified novel influenza A virus with other respiratory manifestations
442696006 – Influenza due to Influenza A virus subtype H1N1
Seasonal and local occurrences of influenza should be considered. Co-circulation of other influenza viruses (eg, human influenza A [H1N1] virus, human influenza A [H3N2] virus, or influenza B virus) with novel H1N1 influenza A will make diagnosis more challenging.